Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
XERS Xeris Pharmaceuticals, Inc. daily Stock Chart
XERS [NASD]
Xeris Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-2.92 Insider Own2.50% Shs Outstand26.52M Perf Week-3.34%
Market Cap245.31M Forward P/E- EPS next Y-2.18 Insider Trans- Shs Float25.15M Perf Month-7.13%
Income-60.10M PEG- EPS next Q-0.76 Inst Own49.10% Short Float5.15% Perf Quarter-41.53%
Sales2.50M P/S98.12 EPS this Y-114.60% Inst Trans1.66% Short Ratio4.46 Perf Half Y-53.61%
Book/sh3.60 P/B2.57 EPS next Y28.80% ROA-52.50% Target Price23.25 Perf Year-
Cash/sh4.25 P/C2.18 EPS next 5Y- ROE-114.20% 52W Range8.67 - 27.98 Perf YTD-45.59%
Dividend- P/FCF- EPS past 5Y- ROI-55.30% 52W High-66.94% Beta-
Dividend %- Quick Ratio11.60 Sales past 5Y- Gross Margin98.30% 52W Low6.69% ATR0.56
Employees90 Current Ratio11.60 Sales Q/Q60.00% Oper. Margin- RSI (14)43.19 Volatility6.47% 6.09%
OptionableNo Debt/Eq0.42 EPS Q/Q-110.10% Profit Margin- Rel Volume0.52 Prev Close9.62
ShortableYes LT Debt/Eq0.42 EarningsFeb 27 Payout- Avg Volume290.07K Price9.25
Recom- SMA20-5.39% SMA50-7.28% SMA200-47.34% Volume151,083 Change-3.85%
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Jul-16-18Initiated Leerink Partners Outperform $24
Jul-16-18Initiated Jefferies Buy $23
Mar-29-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Mar-25-19 08:45AM  Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon Business Wire
Mar-14-19 04:15PM  Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia Business Wire
Mar-12-19 03:36PM  How Many Insiders Bought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares? Simply Wall St.
Mar-06-19 04:10PM  Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress GlobeNewswire
Mar-01-19 04:15PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-20-19 07:30AM  Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-13-19 07:26PM  Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock GlobeNewswire -8.67%
Feb-12-19 04:33PM  Why Molson Coors Brewing, Xeris Pharmaceuticals, and Varonis Systems Slumped Today Motley Fool -21.50%
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
Feb-11-19 04:05PM  Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock GlobeNewswire
Dec-20-18 08:30AM  European Medicines Agency Grants Orphan Drug Designation for Xeris Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS) Business Wire -11.96%
Nov-07-18 08:00AM  Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress GlobeNewswire
Oct-23-18 08:30AM  Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen Business Wire
Aug-17-18 08:30AM  Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris Novel Ready-to-Use Liquid Glucagon Business Wire
Aug-13-18 08:00AM  Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Jul-31-18 07:00AM  Xeris Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire
Jul-30-18 07:00AM  Xeris Pharmaceuticals Announces New Board Members and New Executive to Management Team GlobeNewswire
Jun-26-18 04:15PM  Xeris Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jun-25-18 04:15PM  Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen Business Wire
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 06:31PM  Xeris Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock GlobeNewswire
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that is in Phase II clinical trials for the treatment of congenital hyperinsulinism, post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, and hypoglycemia-associated autonomic failure, as well as for treating hypoglycemia associated with intermittent and chronic conditions, and bi-hormonal artificial pancreas closed-loop systems. In addition, it develops continuous subcutaneous glucagon infusion system of ready-to-use glucagon; ready-to-use diazepam formulation, which is in Phase I clinical trial for the treatment of acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is in pre-clinical stage for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.
open in yahoo | open in reuters | open in google